Literature DB >> 23174001

Access to wound dressings for patients living with epidermolysis bullosa - an Australian perspective.

Louise J Stevens1.   

Abstract

Epidermolysis Bullosa (EB) is a rare genetic skin disorder characterised by fragility and blistering of skin and mucous membranes. Skin can blister and shear away from minimal friction, trauma and every day activities. The disease causes a wide range of complications but wound care is the major challenge to severe EB, and good wound care is an essential part of wound management. The goal of wound care was to choose a product that protects the fragile skin, limits friction, decreases pain and promotes healing. However, access to wound dressings for those people living with EB is challenging. This article discusses the availability of EB dressings in a number of countries around the world and also describes an innovative National Epidermolysis Bullosa Dressings Scheme (NEBDS) in Australia, which aims to improve the quality of life of people with EB, by reducing the financial burden associated with the provision of dressings accordingly.
© 2012 The Authors. International Wound Journal © 2012 Medicalhelplines.com Inc and John Wiley & Sons Ltd.

Entities:  

Keywords:  Dressings; Epidermolysis bullosa; Funding; Skin disorder; Wounds

Mesh:

Year:  2012        PMID: 23174001      PMCID: PMC7950898          DOI: 10.1111/j.1742-481X.2012.01116.x

Source DB:  PubMed          Journal:  Int Wound J        ISSN: 1742-4801            Impact factor:   3.315


  8 in total

Review 1.  Epidermolysis bullosa in Australia and New Zealand.

Authors:  Dédée F Murrell
Journal:  Dermatol Clin       Date:  2010-04       Impact factor: 3.478

Review 2.  Treatment of skin cancers in epidermolysis bullosa.

Authors:  Supriya S Venugopal; Dédée F Murrell
Journal:  Dermatol Clin       Date:  2010-04       Impact factor: 3.478

3.  Medical management of epidermolysis bullosa: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile, 2005.

Authors:  Jemima E Mellerio; Madeline Weiner; Jacqueline E Denyer; Elizabeth I Pillay; Anne W Lucky; Anna Bruckner; Francis Palisson
Journal:  Int J Dermatol       Date:  2007-08       Impact factor: 2.736

Review 4.  Recessive dystrophic epidermolysis bullosa. Part 2: care of the adult patient.

Authors:  Elizabeth M Abercrombie; Claire A Mather; Jennie Hon; Pauline Graham-King; Elizabeth Pillay
Journal:  Br J Nurs       Date:  2008 Mar 27-Apr 9

Review 5.  Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs.

Authors:  Jo-David Fine; Jemima E Mellerio
Journal:  J Am Acad Dermatol       Date:  2009-09       Impact factor: 11.527

6.  The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB.

Authors:  Jo-David Fine; Robin A J Eady; Eugene A Bauer; Johann W Bauer; Leena Bruckner-Tuderman; Adrian Heagerty; Helmut Hintner; Alain Hovnanian; Marcel F Jonkman; Irene Leigh; John A McGrath; Jemima E Mellerio; Dedee F Murrell; Hiroshi Shimizu; Jouni Uitto; Anders Vahlquist; David Woodley; Giovanna Zambruno
Journal:  J Am Acad Dermatol       Date:  2008-04-18       Impact factor: 11.527

Review 7.  Epidermolysis bullosa care in the United Kingdom.

Authors:  Jemima E Mellerio
Journal:  Dermatol Clin       Date:  2010-04       Impact factor: 3.478

Review 8.  Risk of squamous cell carcinoma in junctional epidermolysis bullosa, non-Herlitz type: report of 7 cases and a review of the literature.

Authors:  Wing Yan Yuen; Marcel F Jonkman
Journal:  J Am Acad Dermatol       Date:  2011-05-31       Impact factor: 11.527

  8 in total
  2 in total

1.  Understanding the outcomes of a home nursing programme for patients with epidermolysis bullosa: an Australian perspective.

Authors:  Louise J Stevens; Sue McKenna; Jennifer Marty; Allison J Cowin; Zlatko Kopecki
Journal:  Int Wound J       Date:  2014-12-03       Impact factor: 3.315

2.  Financial burden of epidermolysis bullosa on patients in the United States.

Authors:  Emily S Gorell; Paige W Wolstencroft; Mark P de Souza; Dedee F Murrell; Eleni Linos; Jean Y Tang
Journal:  Pediatr Dermatol       Date:  2020-09-08       Impact factor: 1.588

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.